Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

489
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
489
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

488
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
488
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

375
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
375
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

330
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
330
Hazard Rate01:11

Hazard Rate

345
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.

Journal of the Endocrine Society·2026
Same author

REVEALing New Standards: Low Risk Redefined.

JACC. Heart failure·2026
Same author

Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.

Chest·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.

Science advances·2026
Same author

A Novel Method for the Evaluation of Hypercalciuria in Individuals With Chronic Hypoparathyroidism.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Related Experiment Video

Updated: Dec 22, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

466

Risk stratification in pulmonary arterial hypertension using Bayesian analysis.

Manreet K Kanwar1, Mardi Gomberg-Maitland2, Marius Hoeper3

  • 1Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA, USA.

The European Respiratory Journal
|May 6, 2020
PubMed
Summary

A new machine learning model, PHORA, improves risk prediction for pulmonary arterial hypertension (PAH) patients, outperforming the current REVEAL 2.0 tool. This advanced model enhances survival prediction by considering complex variable relationships.

More Related Videos

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

Related Experiment Videos

Last Updated: Dec 22, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

466
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

Area of Science:

  • Cardiology
  • Pulmonology
  • Machine Learning
  • Biostatistics

Background:

  • Current risk stratification tools for pulmonary arterial hypertension (PAH) have limited predictive accuracy.
  • This limitation stems from the assumption of independent and linear relationships between prognostic variables and outcomes.
  • There is a need for enhanced risk prediction models in PAH management.

Purpose of the Study:

  • To demonstrate the utility of Bayesian network-based machine learning in improving PAH risk stratification.
  • To enhance the predictive ability of the existing REVEAL 2.0 risk stratification tool.
  • To develop a novel risk prediction model named PHORA.

Main Methods:

  • A tree-augmented naïve Bayes model (PHORA) was developed using data from the REVEAL registry.
  • PHORA utilizes the same variables and cut-points as the REVEAL 2.0 tool for predicting 1-year survival.
  • Internal and external validation was performed across the REVEAL, COMPERA, and PHSANZ registries.

Main Results:

  • PHORA achieved an Area Under the Curve (AUC) of 0.80 for 1-year survival prediction, outperforming REVEAL 2.0 (AUC 0.76).
  • External validation showed AUCs of 0.74 (COMPERA) and 0.80 (PHSANZ).
  • PHORA demonstrated excellent discrimination between low-, intermediate-, and high-risk groups in all registries.

Conclusions:

  • The Bayesian network-derived PHORA model shows improved risk prediction discrimination in PAH.
  • Bayesian networks effectively account for interrelationships between clinical variables and outcomes.
  • PHORA offers enhanced predictive capabilities and tolerance to missing data in PAH risk assessment.